Physician profile
William Reeves
NPI 1396719126
$5,940.59
in general payments reported to CMS, 2019-2025
35 companies · $968 in 2025
The $968 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $343 · 2020: $377 · 2021: $675 · 2022: $1,565 · 2023: $1,015 · 2024: $997 · 2025: $968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,979.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,287.31 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $1,103.59 | 2023-2025 | Myfembree |
| Hologic Sales and Service, LLC | $402.43 | 2019-2025 | Aptima, Thinprep 2000 Processor, Myosure Tissue Removal Device |
| Channel Medsystems, INC. | $324.14 | 2022-2025 | |
| Myovant Sciences INC. | $233.48 | 2021-2022 | |
| Optumhealth Care Solutions, LLC | $230.21 | 2023-2025 | Eitan Medical, Vivify Health Care Team Portal 001, Vivify Health Care Team Portal |
| Exeltis, USA INC. | $226.96 | 2021-2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $215.40 | 2019-2025 | |
| Shield Therapeutics INC | $213.68 | 2023-2025 | Accrufer |
| Astellas Pharma US INC | $202.11 | 2023-2025 | Veozah |
| Agile Therapeutics, INC. | $143.44 | 2021-2023 | Twirla |
| Sage Therapeutics, LLC | $138.79 | 2020-2024 | |
| Evofem Biosciences, INC. | $133.66 | 2021-2022 | |
| Organon LLC | $123.14 | 2022-2025 | Nexplanon |
| Mylan Pharmaceuticals INC. | $115.23 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $106.27 | 2023-2025 | |
| Pfizer INC. | $104.99 | 2019-2024 | |
| Millicent US INC | $88.35 | 2019-2025 | Intrarosa, Femring, Femlyv |
| Dexcom, INC. | $86.18 | 2025 | Dexcom G6 Transmitter |
| Avion Pharmaceuticals | $81.41 | 2019-2022 | |
| Therapeuticsmd, INC. | $75.25 | 2019-2022 | |
| Scynexis, INC. | $51.67 | 2022 | |
| Duchesnay USA Incorporated | $42.54 | 2019 | |
| Aspira Women'S Health INC | $36.88 | 2022 | |
| Merck Sharp & Dohme LLC | $26.52 | 2020 | |
| Lupin INC. | $25.86 | 2019-2020 | |
| Sanara Medtech INC. | $23.31 | 2025 | Celleraterx |
| Allergan, INC. | $21.39 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $15.45 | 2021 | |
| Axonics, INC. | $14.99 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $14.97 | 2022 | |
| Abbott Laboratories | $12.91 | 2020 | |
| Minerva Surgical, INC | $11.13 | 2019 | |
| Meditrina | $6.95 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$4.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Reeves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.